Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Enliven Therapeutics Inc

ELVN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$58.82

▲ +1.31%

Market Cap $4.31B · Vol 116.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$4.31B

Mid Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

-1.53%

YoY

RSI (14)

69.55

Momentum

Beta

0.26

vs Market

52W High

$62.32

5.62% below

52W Low

$14.83

296.63% above

Volume

116.01K

Avg 257.40K

P/B

1.99

Price-to-book

ROE

N/A

Return on equity

Free Float

84.25%

Public shares

Shariah Compliance8 STANDARDS

✗ Enliven Therapeutics Inc (ELVN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ELVN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.71%

+13.71%

+36.54%

+120.13%

YTD

+281.95%

+197.52%

+257.13%

+225.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-103,694,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-25.86% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.99
P/FCF	N/A
EPS Growth	-1.53%
Outstanding Shares	73.27M

Technical Indicators

50-Day SMA	$50.40
200-Day SMA	$34.71
RSI (14)	69.55
Beta	0.26
52-Week High	$62.32
52-Week Low	$14.83

Volume Today	116.01K
Avg Daily Volume (30D)	257.40K
Relative Volume	0.45x
Volatility (10D)	41.51
Volatility (30D)	39.09
Free Float	84.25%

Analyst Consensus

BUY

Current Price $58.82

Mean Target $71.90

52W Low$14.83 52W High$62.32

Current

Target

$14.83 $62.32

Current Analyst target

+22.24% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00CP3BDF2

ISINUS29337E1029

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. It is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML). ELVN-001 is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI). The Company's second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations.